Gruberg L, Mehran R, Waksman R, Dangas G, Fuchs S, Wu H, Kent K M, Pichard A D, Satler L F, Stone G W, Leon M B
Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC 20010, USA.
Am J Cardiol. 2001 Jun 15;87(12):1356-60. doi: 10.1016/s0002-9149(01)01552-1.
We evaluated the short- and long-term clinical outcomes of 326 consecutive patients with chronic renal failure, not on dialysis, who had creatine kinase (CK)-myocardial band (MB) fraction elevation after successful percutaneous coronary intervention in a native coronary artery. Based on peak CK-MB levels measured after intervention, patients were divided into 3 groups: no elevation (group 1, n = 184), 1 to 3 x upper normal levels (group 2, n = 72), and >3 x upper normal levels (group 3, n = 70). Baseline clinical and angiographic characteristics were similar among the 3 groups. Angiographic success was similar among the 3 groups, although there was a significantly higher use of intra-aortic balloon pump in patients who had postprocedural CK-MB >3 x normal values and a higher rate of in-hospital complications, i.e., repeat catheterization, repeat target lesion intervention, pulmonary edema, renal function deterioration, emergency dialysis, and major bleeding complications. At 1-year follow-up, mortality rates were significantly higher in these patients (35.4% vs 22.0% for patients with CK-MB 1 to 3 x normal values and 16.7% for patients without CK-MB elevation, p = 0.007). Multivariate analysis showed that CK-MB >3 x normal (odds ratio 3.04; 95% confidence interval 1.41 to 6.57, p = 0.005) and intra-aortic balloon pump (odds ratio 1.49; confidence interval 1.15 to 1.93, p = 0.002) were independent predictors of late mortality. Therefore, patients with chronic renal failure who had CK-MB elevation >3 x the upper normal limit after a successful percutaneous coronary intervention had a higher incidence of in-hospital complications and a significantly higher mortality rate at 1-year follow-up than patients without CK-MB elevation or with <3 x normal CK-MB elevation.
我们评估了326例连续性慢性肾衰竭且未接受透析治疗的患者的短期和长期临床结局,这些患者在成功进行原位冠状动脉经皮冠状动脉介入治疗后肌酸激酶(CK)-心肌型同工酶(MB)分数升高。根据介入治疗后测得的CK-MB峰值水平,患者被分为3组:无升高组(第1组,n = 184)、1至3倍正常上限水平组(第2组,n = 72)和>3倍正常上限水平组(第3组,n = 70)。3组患者的基线临床和血管造影特征相似。3组患者的血管造影成功率相似,尽管术后CK-MB>3倍正常值的患者主动脉内球囊泵的使用显著增加,且住院并发症发生率更高,即重复导管插入术、重复靶病变干预、肺水肿、肾功能恶化、紧急透析和严重出血并发症。在1年随访时,这些患者的死亡率显著更高(CK-MB为1至3倍正常水平的患者死亡率为35.4%,CK-MB无升高的患者死亡率为22.0%,无CK-MB升高的患者死亡率为16.7%,p = 0.007)。多因素分析显示,CK-MB>3倍正常水平(比值比3.04;95%置信区间1.41至6.57,p = 0.005)和主动脉内球囊泵(比值比1.49;置信区间1.15至1.93,p = 0.002)是晚期死亡率的独立预测因素。因此,与CK-MB无升高或CK-MB升高<3倍正常上限的患者相比,成功进行经皮冠状动脉介入治疗后CK-MB升高>3倍正常上限的慢性肾衰竭患者住院并发症发生率更高,且在1年随访时死亡率显著更高。